117 related articles for article (PubMed ID: 22262588)
1. The organizational structure and governing principles of the Food and Drug Administration's Mini-Sentinel pilot program.
Forrow S; Campion DM; Herrinton LJ; Nair VP; Robb MA; Wilson M; Platt R
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():12-7. PubMed ID: 22262588
[TBL] [Abstract][Full Text] [Related]
2. A policy framework for public health uses of electronic health data.
McGraw D; Rosati K; Evans B
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():18-22. PubMed ID: 22262589
[TBL] [Abstract][Full Text] [Related]
3. The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction.
Platt R; Carnahan RM; Brown JS; Chrischilles E; Curtis LH; Hennessy S; Nelson JC; Racoosin JA; Robb M; Schneeweiss S; Toh S; Weiner MG
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():1-8. PubMed ID: 22262586
[TBL] [Abstract][Full Text] [Related]
4. Design considerations, architecture, and use of the Mini-Sentinel distributed data system.
Curtis LH; Weiner MG; Boudreau DM; Cooper WO; Daniel GW; Nair VP; Raebel MA; Beaulieu NU; Rosofsky R; Woodworth TS; Brown JS
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():23-31. PubMed ID: 22262590
[TBL] [Abstract][Full Text] [Related]
5. The Food and Drug Administration's Post-Licensure Rapid Immunization Safety Monitoring program: strengthening the federal vaccine safety enterprise.
Nguyen M; Ball R; Midthun K; Lieu TA
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():291-7. PubMed ID: 22262619
[TBL] [Abstract][Full Text] [Related]
6. The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety.
Robb MA; Racoosin JA; Sherman RE; Gross TP; Ball R; Reichman ME; Midthun K; Woodcock J
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():9-11. PubMed ID: 22262587
[No Abstract] [Full Text] [Related]
7. Statistical approaches to group sequential monitoring of postmarket safety surveillance data: current state of the art for use in the Mini-Sentinel pilot.
Cook AJ; Tiwari RC; Wellman RD; Heckbert SR; Li L; Heagerty P; Marsh T; Nelson JC
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():72-81. PubMed ID: 22262595
[TBL] [Abstract][Full Text] [Related]
8. Preface to supplement. Active surveillance of vaccine safety in the US Food and Drug Administration's Mini-Sentinel program: identification of exposures and outcomes.
Vaccine; 2013 Dec; 31 Suppl 10():K1. PubMed ID: 24331068
[No Abstract] [Full Text] [Related]
9. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
Roller ST; Pippins RR; Ngai JW
Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
[TBL] [Abstract][Full Text] [Related]
10. A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent.
Fireman B; Toh S; Butler MG; Go AS; Joffe HV; Graham DJ; Nelson JC; Daniel GW; Selby JV
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():282-90. PubMed ID: 22262618
[TBL] [Abstract][Full Text] [Related]
11. Mini-Sentinel's systematic reviews of validated methods for identifying health outcomes using administrative and claims data: methods and lessons learned.
Carnahan RM; Moores KG
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():82-9. PubMed ID: 22262596
[TBL] [Abstract][Full Text] [Related]
12. Collaboration in electronic medical evidence development: a case study of the Social Security Administration's MEGAHIT System.
Feldman SS; Horan TA
Int J Med Inform; 2011 Aug; 80(8):e127-40. PubMed ID: 21333588
[TBL] [Abstract][Full Text] [Related]
13. A COVID-19-ready public health surveillance system: The Food and Drug Administration's Sentinel System.
Cocoros NM; Fuller CC; Adimadhyam S; Ball R; Brown JS; Dal Pan GJ; Kluberg SA; Lo Re V; Maro JC; Nguyen M; Orr R; Paraoan D; Perlin J; Poland RE; Driscoll MR; Sands K; Toh S; Yih WK; Platt R;
Pharmacoepidemiol Drug Saf; 2021 Jul; 30(7):827-837. PubMed ID: 33797815
[TBL] [Abstract][Full Text] [Related]
14. "Black box" 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk.
Murphy S; Roberts R
J Allergy Clin Immunol; 2006 Jan; 117(1):34-9. PubMed ID: 16387581
[TBL] [Abstract][Full Text] [Related]
15. Medical device warning letter draft pilot; availability--FDA. Notice.
Fed Regist; 1998 Aug; 63(166):45821-5. PubMed ID: 10182695
[TBL] [Abstract][Full Text] [Related]
16. New FDA reporting rule means new concerns.
Healthc Hazard Mater Manage; 1996 Mar; 9(6):1-4. PubMed ID: 10155771
[No Abstract] [Full Text] [Related]
17. What you should know about device recalls.
OR Manager; 2002 Apr; 18(4):21. PubMed ID: 11962164
[No Abstract] [Full Text] [Related]
18. Finding value in the U.S. Food and Drug Administration's Fast Track program.
Reichert JM; Rochon SL; Zhang BD
Drug News Perspect; 2009; 22(1):53-8. PubMed ID: 19209299
[TBL] [Abstract][Full Text] [Related]
19. Confidentiality laws and secrecy in medical research: improving public access to data on drug safety.
Kesselheim AS; Mello MM
Health Aff (Millwood); 2007; 26(2):483-91. PubMed ID: 17339677
[TBL] [Abstract][Full Text] [Related]
20. The role of databases in drug postmarketing surveillance.
Rodriguez EM; Staffa JA; Graham DJ
Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
